|
|
|
|
|
|
|
|
|
|
With a handful of possible exceptions, Diamandis wrote, "very few, if any, molecules have been identified that are expressed only by a cancer tissue but not by the corresponding normal tissue."
Cancer biomarkers are missing in action despite the availability of "highly sophisticated and powerful technologies" to discover them, as well as large investments, Diamandis wrote, adding that the last biomarker approved by the FDA -- in 2009 -- was HE4 protein, indicated for monitoring recurrence but not early detection of ovarian cancer."
Action Points
- Note that this commentary documents the hazards of reports on promising biomarkers for cancer screening.
- The author points out that one of the major problems is finding biomarkers released in significant amounts from asymptomatic (usually small) tumors, but not from normal tissues.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.